logo

PHGE

BiomX·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

PHGE fundamentals

BiomX (PHGE) released its earnings on Nov 12, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.29 (YoY +6.45%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.29
+6.45%
Report date
Nov 12, 2025
PHGE Earnings Call Summary for Q3,2025
  • BX004 Regulatory Milestone: FDA clinical hold resolved via nebulizer data submission; European trial continues. FDA recognizes unmet need for Pseudomonas in CF, guiding Phase III strategy.
  • BX011 Breakthrough: FDA clears path for off-the-shelf phage therapy in DFI, targeting 160,000 annual U.S. cases. DHA supports dual-use for combat wounds with $40M prior backing.
  • Financial Resilience: $8.1M cash runway into Q1 2026; R&D and G&A expenses down 13% and 25% YoY, respectively.
  • Strategic Growth: Leveraging phage therapy momentum; Phase IIb data expected Q1 2026 to inform Phase III design and potential partnerships.
EPS
Revenue

Revenue & Expenses

Key Indicators

BiomX (PHGE) key financial stats and ratios, covering profitability, financial health, and leverage.
BiomX (PHGE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
BiomX (PHGE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
BiomX (PHGE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does BiomX (PHGE) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track BiomX (PHGE) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield